Fifth Third Bancorp’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Fifth Third Bancorp’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000	Closed	-$24K	–	2680
2021 Q4	$24K	Sell	1,000 -500	-33%	-$13.9K	﹤0.01%	1789
2021 Q3	$46K	Buy	+1,500	New	+$45.3K	﹤0.01%	1477
2019 Q1	–	Sell	-400	Closed	-$8K	–	2167
2018 Q4	$8K	Hold	400	–	–	﹤0.01%	1828
2018 Q3	$10K	Hold	400	–	–	﹤0.01%	1823
2018 Q2	$10K	Hold	400	–	–	﹤0.01%	1876
2018 Q1	$12K	Buy	400 +100	+33%	+$2.83K	﹤0.01%	1828
2017 Q4	$7K	Hold	300	–	–	﹤0.01%	1911
2017 Q3	$8K	Buy	300 +200	+200%	+$4.86K	﹤0.01%	1827
2017 Q2	$2K	Buy	+100	New	+$2.26K	﹤0.01%	2037

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Fifth Third Bancorp's CNCR Position: Q1 2022 in Review

Fifth Third Bancorp sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2022, closing a stake of 1,000 shares — an estimated $24K sold.

Fifth Third Bancorp first reported a position in CNCR in Q2 2017 and held it in 9 quarters. The position peaked at $46K in Q3 2021. 20 funds tracked by Wall St. Rank hold CNCR as of Q1 2022.

Fifth Third Bancorp reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2022 after selling out during the quarter.
Fifth Third Bancorp sold 1,000 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q1 2022, an estimated $24K.
Fifth Third Bancorp first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2017 and held it in 9 quarters.
Fifth Third Bancorp's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $46K in Q3 2021.
20 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2022.

Based on Fifth Third Bancorp's 13F filing for Q1 2022, filed 19 Apr 2022.